In the past week, ARQT stock has gone down by -0.11%, with a monthly decline of -19.15% and a quarterly plunge of -0.04%. The volatility ratio for the week is 12.06%, and the volatility levels for the last 30 days are 9.82% for Arcutis Biotherapeutics Inc The simple moving average for the past 20 days is -13.12% for ARQT’s stock, with a 13.26% simple moving average for the past 200 days.
Is It Worth Investing in Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Right Now?
Company’s 36-month beta value is 1.91.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ARQT is 104.41M, and currently, short sellers hold a 14.01% ratio of that floaft. The average trading volume of ARQT on April 15, 2025 was 2.50M shares.
ARQT) stock’s latest price update
Arcutis Biotherapeutics Inc (NASDAQ: ARQT)’s stock price has soared by 2.59 in relation to previous closing price of 12.94. Nevertheless, the company has seen a loss of -0.11% in its stock price over the last five trading days. globenewswire.com reported 2025-04-10 that WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper, Arcutis’ chief financial officer (CFO) is retiring from the Company and Latha Vairavan, currently vice president and controller, will assume the role of CFO and join the executive team as part of a planned succession. Mr. Topper will continue to serve as CFO until the filing of the Company’s first quarter 10-Q and will provide transition support through his departure on May 15, 2025.
Analysts’ Opinion of ARQT
Many brokerage firms have already submitted their reports for ARQT stocks, with H.C. Wainwright repeating the rating for ARQT by listing it as a “Buy.” The predicted price for ARQT in the upcoming period, according to H.C. Wainwright is $19 based on the research report published on December 30, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see ARQT reach a price target of $15. The rating they have provided for ARQT stocks is “Buy” according to the report published on August 28th, 2024.
Mizuho gave a rating of “Buy” to ARQT, setting the target price at $8 in the report published on January 03rd of the previous year.
ARQT Trading at -6.57% from the 50-Day Moving Average
After a stumble in the market that brought ARQT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.21% of loss for the given period.
Volatility was left at 9.82%, however, over the last 30 days, the volatility rate increased by 12.06%, as shares sank -15.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.07% upper at present.
During the last 5 trading sessions, ARQT rose by +1.28%, which changed the moving average for the period of 200-days by +42.89% in comparison to the 20-day moving average, which settled at $15.29. In addition, Arcutis Biotherapeutics Inc saw -4.70% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARQT starting from Welgus Howard G., who sale 10,000 shares at the price of $15.12 back on Apr 01 ’25. After this action, Welgus Howard G. now owns 121,944 shares of Arcutis Biotherapeutics Inc, valued at $151,236 using the latest closing price.
Topper David Joseph, the Chief Financial Officer of Arcutis Biotherapeutics Inc, sale 9,600 shares at $15.80 during a trade that took place back on Apr 02 ’25, which means that Topper David Joseph is holding 182,774 shares at $151,698 based on the most recent closing price.
Stock Fundamentals for ARQT
Current profitability levels for the company are sitting at:
- -0.65 for the present operating margin
- 0.9 for the gross margin
The net margin for Arcutis Biotherapeutics Inc stands at -0.71. The total capital return value is set at -0.48. Equity return is now at value -113.76, with -40.58 for asset returns.
Based on Arcutis Biotherapeutics Inc (ARQT), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at -1.01. The debt to equity ratio resting at 0.7. The interest coverage ratio of the stock is -4.73.
Currently, EBITDA for the company is -109.62 million with net debt to EBITDA at -0.36. When we switch over and look at the enterprise to sales, we see a ratio of 8.15. The receivables turnover for the company is 2.69for trailing twelve months and the total asset turnover is 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.15.
Conclusion
In a nutshell, Arcutis Biotherapeutics Inc (ARQT) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
